Avacta Group Plc · LSE:AVCT
Avacta — Q2 2025 Earnings Presentation
9 slides from Avacta's earnings presentation, Sep 30, 2025
Slide 1: Expanding the reach of highly potent cancer therapies
Expanding the reach of highly potent cancer therapies Interim Results September 30, 2025
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding the Company’s research, preclinical and clinical development activities, plans and projected timelines for AVA6000 and the Avacta pipeline, plans re
Slide 3: Recent R&D Highlights
Recent R&D Highlights • Clinical stage programs continue to advance with enrolment ongoing in Phase 1b expansion cohorts in the faridoxorubicin1 (FAP-Dox, AVA6000) program. The initial clinical activity observed in Phase 1b is highly encouraging. • FAP-EXd (AVA6103) remains on track to dose the firs
Slide 4: FAP-EXd Update: Multiple Durable Complete Responses Continue
FAP-EXd Update: Multiple Durable Complete Responses Continue Weeks After Dosing FAP-EXd (AVA6103) Treatment Results in Complete Responses in a low-FAP Model FAP-EXd (AVA6103) Results in Complete Responses 2.50 Vehicle Exatecan FAP-EXd (AVA6103) 2.00 100 Tumor Volume (cm3) 100 100 Murine FAP expressi
Slide 5: FAP-EXd (AVA6103) Planned for Phase 1 to Initiate in Q1 2026
FAP-EXd (AVA6103) Planned for Phase 1 to Initiate in Q1 2026 2024 2025 2026 2027 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Candidate selection Pre-IND IND GMP DS GMP DP manufacture manufacture Phase 1 first patient in (FPI) Dose range GLP toxicology finding studies finding studies Phase 1 Milestones &
Slide 6: Financial Update
Financial Update Period end cash and cash-equivalent balances were £12.65 million (30 June 2024: £28.56 million; 31 December 2024: £12.87 million). Cash outflow from operations and working capital movements were £12.14 million (H1 2024: £12.60 million; FY 2024: £26.05 million) and cash inflow from i
Slide 7: Upcoming Key Data Catalysts 2025-2026
Upcoming Key Data Catalysts 2025-2026 FAP-Dox (Program 1) FAP-EXd (Program 2) Pipeline Program 3 Data Catalysts Data Catalysts Data Catalyst FAP-Dox (AVA6000) advances to FAP-EXd (AVA6103) planned to Identify third pipeline program expansion cohorts (Phase 1b, initiate dosing in the Phase 1 and adva
Slide 8: Strategic Opportunities and Company Outlook
Strategic Opportunities and Company Outlook ▪ Collaboration with Tempus AI delivered on overall market opportunity for pre|CISION medicines capable of reaching many patients globally as well as smarter identification of patient populations for the next pre|CISION medicine, FAP-EXd (AVA6103) ▪ Engagi
Slide 9: Thank You
Thank You © AVACTA LIFE SCIENCES LIMITED 2024